The company has been committed to the modernization and internationalization of traditional Chinese medicine for a long time, and has continuously improved the technical connotation of traditional Chinese medicine by using new technologies, new dosage forms and new excipients of modern drug research, and formed leading technical features such as "large-scale application of extraction and refining technology represented by membrane separation and countercurrent extraction", "modernization of quality control technology of traditional Chinese medicine represented by fingerprint" and "serialization of new dosage forms of traditional Chinese medicine led by injections and soft capsules", thus establishing a leading position in the domestic traditional Chinese medicine industry. And has formed a core competitive advantage in gynecology, pediatrics, orthopedics, anti-tumor, cardiovascular and cerebrovascular fields.
By the end of 2006, the company had independently developed 35 national-level new drugs, including 2 in the second category, 8 in the third category and 25 in the fourth category. It has successively undertaken three national "863" scientific research projects, two high-tech industrialization demonstration projects of the State Planning Commission, two major special projects of the State Economic and Trade Commission, and the national Spark Plan and Torch Plan 1 1. Declare domestic and foreign patents 1 14, and the number of invention patents granted ranks eighth among domestic enterprises. The company has successfully developed nearly ten kinds of new soft capsule series drugs such as Liuwei Dihuang Soft Capsule, and the soft capsule preparation technology has reached the leading level in China. Reduning injection and Tongan injection independently developed are representative varieties under the guidance of the latest national injection certification standards; Guizhifu Capsule, the leading product of the company, has been approved for the second phase of bed monitoring test in the United States.
The company has strong research and development strength. The enterprise product research and development center consists of seven departments: preparation research institute, drug research institute, pharmacology research institute, technology research institute, clinical research department, information examination and approval department and detection and analysis department. The laboratory covers an area of 10000m2, and the experimental equipment is worth 50 million yuan. It has a scientific and technological development team composed of1more than 30 scientific and technological personnel with bachelor degree or above, including doctor 1 1 person, master 12 person and 8 senior engineers. It can be engaged in information system construction, prescription screening, pharmacological screening, process research, quality standard research, pilot scale-up research, clinical research and drug research in the whole process of approval and registration. The company has established eight laboratories, including Natural Medicine Laboratory, biochemical drugs Laboratory and Jiangsu Zhongkang Pharmaceutical Technology Development Company, with top domestic scientific research institutions such as Shanghai Institute of Organic Chemistry of Chinese Academy of Sciences, Peking University, China Pharmaceutical University and Nanjing University of Chinese Medicine. At present, the varieties under research mainly involve the fields of anti-tumor, anti-infection and cardiovascular and cerebrovascular treatment. In 2002, the company's R&D center was successively recognized as "National Postdoctoral Research Center" and "National Enterprise Technology Center".
The company's modern Chinese medicine production base has a workshop area of 85,000 square meters and a comprehensive preparation workshop of 58,000 square meters. It has 13 advanced production lines for capsules, oral liquids, Chinese medicine injections, tablets, granules, small-volume injections, freeze-dried powder injections and tinctures, as well as supporting material preparation centers, quality inspection centers, power centers and management centers. The annual output is 65.438+0.2 billion hard capsules, 65.438+0.7 billion oral liquids, 65.438+0.7 billion soft capsules, 30 million injections of traditional Chinese medicine, 65.438+0.5 billion tablets and 654.38+0.00 tons of granules. The pretreatment workshop of traditional Chinese medicine in the production base adopts advanced pretreatment technology and means of traditional Chinese medicine extraction at home and abroad, equipped with monitoring system and online cleaning facilities, which realizes the pipeline and functionalization of traditional Chinese medicine extraction, can produce a variety of traditional Chinese medicine extracts or single particles of traditional Chinese medicine, has the annual production capacity of processing and extracting 10,000 tons of traditional Chinese medicine, and is in a leading position in the same industry in China.
The company has a professional marketing team of more than 1500 people, which is divided into four sections: gynecological line, orthopedic line, anti-infection line, retail and class C terminal. We have set up 3 1 sales branches and 1 sales offices in 28 provinces and cities across the country, and established long-term and stable business relations with more than 800 pharmaceutical merchants across the country, covering nearly 50,000 kinds of products. The company has the right of self-export, and some products are exported to Japan, South Korea, Southeast Asia and other countries and regions, with distribution centers and branches in Hong Kong, Canada and Australia.
production base